Use of Octreotide in the Acute Management of Bleeding Esophageal Varices
Author(s) -
Daniel Sadowski
Publication year - 1997
Publication title -
canadian journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
eISSN - 2291-2797
pISSN - 2291-2789
DOI - 10.1155/1997/156920
Subject(s) - octreotide , medicine , esophageal varices , somatostatin , varices , ligation , portal hypertension , terlipressin , gastroenterology , surgery , cirrhosis , hepatorenal syndrome
Acute hemorrhage from esophageal varices is a medical emergency; despite early diagnosis and treatment the associated hospital mortality remains high. The clinical research summarized in this paper shows that octreotide has a beneficial effect on portal hemodynamics in cirrhotic patients. In randomized controlled trials octreotide has been effective in halting initial hemorrhage and in preventing reoccurrence of bleeding. Somatostatin and octreotide appear to be equivalent in terms of therapeutic efficacy but octreotide is the less expensive option. For suspected variceal bleeding an octreotide infusion should be initiated immediately. To prevent further bleeding the drug should be continued for two to five days after endoscopic variceal ligation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom